Home/Pipeline/CEP-40783

CEP-40783

Rheumatoid Arthritis

Phase IIActive

Key Facts

Indication

Rheumatoid Arthritis

Phase

Phase II

Status

Active

Company

Celon Pharma

About Celon Pharma

Celon Pharma's mission is to develop and provide innovative therapies for diseases with significant unmet medical needs, primarily in oncology and CNS, while maintaining financial stability through its generic drug operations. Its key achievement is building a fully integrated, GMP/GLP-compliant biopharma platform in Poland, supporting a pipeline of 11 proprietary drug candidates. The company's strategy is defined by this self-funded, end-to-end model, which reduces external dependencies and aims to capture full value from its R&D successes. This approach has established Celon as a unique and strategically important player in the European biopharmaceutical landscape.

View full company profile

Therapeutic Areas

Oncology Central Nervous System (CNS)

Other Rheumatoid Arthritis Drugs

Drug	Company	Phase	Status
Early Detection Test for Rheumatoid Arthritis	Age Labs	Development	Active
Piclidenoson (CF101)	Can Fite Biopharma	Phase II/III	Previously Active
ERNA-201	Eterna Therapeutics	Preclinical	Active Discovery/Research
Tc99m Tilmanocept	Navidea Biopharmaceuticals	Phase 2/3	Jeopardized (Bankruptcy)
Targeted Immunotherapy for Rheumatoid Arthritis (via Arthritis4Cure)	LFB	Pre-clinical	Development (Partnership)
EYD-001 (Takinib analog)	EydisBio	Preclinical	In vivo efficacy and pilot safety in progress
LFD-200	Lifordi Immunotherapeutics	Phase 1	Active
MEV-N01	Mesenbio	Pre-clinical	Active
CIT-013	Citryll	Phase 2a	Active
Restem-L	Restem	Phase 2	Active
ASIT Platform	Ahead Therapeutics	Pre-clinical	Active
AX-158	Artax Biopharma	Phase 2	Active